+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteogenesis Imperfecta (Genitourinary Disorders) - Drugs In Development, 2021

  • ID: 5359606
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 90 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Amgen Inc
  • Aptacure Therapeutics Ltd
  • Beryl Therapeutics Inc
  • Bone Therapeutics SA
  • Genzyme Corp
  • Keros Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteogenesis Imperfecta (Genitourinary Disorders) - Drugs In Development, 2021, provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Osteogenesis Imperfecta (Genitourinary Disorders) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 6 and 1 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • Aptacure Therapeutics Ltd
  • Beryl Therapeutics Inc
  • Bone Therapeutics SA
  • Genzyme Corp
  • Keros Therapeutics Inc
Introduction
  • Report Coverage
Osteogenesis Imperfecta - Overview

Osteogenesis Imperfecta - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Osteogenesis Imperfecta - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Aptacure Therapeutics Ltd
  • Beryl Therapeutics Inc
  • Bone Therapeutics SA
  • Castle Creek Biosciences Inc
  • Genzyme Corp
  • Keros Therapeutics Inc
  • Mereo Biopharma Group Plc
  • Mesentech Inc
  • Nano Intelligent Biomedical Engineering Corp
Osteogenesis Imperfecta - Drug Profiles

ALLOB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Aptamer to Inhibit Sclerostin for Osteogenesis Imperfecta - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CCB-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
denosumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
fresolimumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
HU-671 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
KER-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
MES-1007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
romosozumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
setrusumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Synthetic Peptide for Osteogenesis Imperfecta - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Osteogenesis Imperfecta - Dormant Projects

Osteogenesis Imperfecta - Discontinued Products

Osteogenesis Imperfecta - Product Development Milestones

Featured News & Press Releases
  • Sep 24, 2020: Mereo BioPharma receives FDA Rare Pediatric Disease Designation for setrusumab for the treatment of osteogenesis imperfecta
  • Sep 11, 2020: Keros Therapeutics presents results from preclinical studies investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
  • Feb 28, 2020: Mereo BioPharma announces positive feedback from type B end-of-phase 2 meeting with the FDA and outlines pivotal phase 3 pediatric study design for setrusumab in osteogenesis imperfecta
  • Jan 14, 2020: Mereo BioPharma announces additional positive data from phase 2b ASTEROID study of setrusumab in adults with osteogenesis imperfecta and provides update on regulatory progress
  • Nov 11, 2019: Mereo Biopharma’s Setrusumab demonstrates dose-dependent bone building and trend in fracture reduction in phase 2b ASTEROID study in adults with osteogenesis imperfecta
  • Oct 23, 2019: HKBU drug the first in Hong Kong to be granted orphan drug designation by the US FDA
  • Sep 04, 2019: Mereo BioPharma announces Setrusumab 6-Month Phase 2b Data in Osteogenesis Imperfecta selected for Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting
  • Jun 03, 2019: Mereo reports positive data of setrusumab in Phase IIb open label arm
  • Oct 15, 2018: Completion of patient enrolment in phase 2b study of BPS-804 for the treatment of osteogenesis imperfecta
  • Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta
  • May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease
  • Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme
  • Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for Osteogenesis Imperfecta
  • Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for osteogenesis imperfecta
  • Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Osteogenesis Imperfecta, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Osteogenesis Imperfecta - Pipeline by Amgen Inc, 2021
  • Osteogenesis Imperfecta - Pipeline by Aptacure Therapeutics Ltd, 2021
  • Osteogenesis Imperfecta - Pipeline by Beryl Therapeutics Inc, 2021
  • Osteogenesis Imperfecta - Pipeline by Bone Therapeutics SA, 2021
  • Osteogenesis Imperfecta - Pipeline by Castle Creek Biosciences Inc, 2021
  • Osteogenesis Imperfecta - Pipeline by Genzyme Corp, 2021
  • Osteogenesis Imperfecta - Pipeline by Keros Therapeutics Inc, 2021
  • Osteogenesis Imperfecta - Pipeline by Mereo Biopharma Group Plc, 2021
  • Osteogenesis Imperfecta - Pipeline by Mesentech Inc, 2021
  • Osteogenesis Imperfecta - Pipeline by Nano Intelligent Biomedical Engineering Corp, 2021
  • Osteogenesis Imperfecta - Dormant Projects, 2021
  • Osteogenesis Imperfecta - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Osteogenesis Imperfecta, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Amgen Inc
  • Aptacure Therapeutics Ltd
  • Beryl Therapeutics Inc
  • Bone Therapeutics SA
  • Castle Creek Biosciences Inc
  • Genzyme Corp
  • Keros Therapeutics Inc
  • Mereo Biopharma Group Plc
  • Mesentech Inc
  • Nano Intelligent Biomedical Engineering Corp
Note: Product cover images may vary from those shown
Adroll
adroll